Oncology

News

AstraZeneca builds in cancer ADCs again, with LaNova deal

AstraZeneca has looked to China for another antibody-drug conjugate (ADC) candidate for cancer, paying $55 million for rights to a preclinical candidate from Shanghai-base

News

Sobi sizes up $1.7bn merger with blood cancer biotech CTI

Swedish Orphan Biovitrum (Sobi) has agreed a $1.7 billion merger deal to acquire CTI BioPharma and its recently-approved Vonjo drug for people with blood cancer myelofibro

News

XinThera buy builds Gilead’s cancer, inflammation pipeline

Gilead Sciences has bulked up its early-stage R&D portfolio with an agreement to buy XinThera, adding drugs targeting PARP for oncology and MK2 for inflammatory diseas

News

Novartis cuts 10% of R&D projects in ‘focused’ strategy

Novartis revealed this morning that it has decided to trim back its R&D pipeline by around 10% to 136 projects, as it continues its transition into a pure-play innovat

News

BMS goes down the Tubulis route for cancer ADCs

Bristol-Myers Squibb has formed another alliance focusing on antibody-drug conjugates (ADCs) for solid tumours, paying German biotech Tubulis $22.75 million upfront to get

News

FDA clears Gamida’s cord blood therapy for cancer patients

The FDA has approved a stem cell-based therapy for cancer patients from Israeli biotech Gamida Cell that is designed to help them recover more quickly from aggressive chem

AstraZeneca builds in cancer ADCs again, with LaNova deal

Sobi sizes up $1.7bn merger with blood cancer biotech CTI

XinThera buy builds Gilead’s cancer, inflammation pipeline

Novartis cuts 10% of R&D projects in ‘focused’ strategy

BMS goes down the Tubulis route for cancer ADCs

FDA clears Gamida’s cord blood therapy for cancer patients

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

How to meet your physicians where they are online

Oncology

Editor's Picks